COMMUNIQUÉS West-GlobeNewswire

Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
03/02/2026
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its [...]
Beghou Names Meredith Ressi as President and Chief Growth Officer
03/02/2026
Appointment reflects Beghou’s focus on scaling intelligently with integrated teams and technology to support clients throughout their commercialization journey EVANSTON, Ill., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Beghou , [...]
MedRisk Acquires Horizon Casualty Services
03/02/2026
Strengthens MedRisk’s ability to deliver better outcomes and an elevated experience WEST CONSHOHOCKEN, Pa., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MedRisk, a leading provider of managed care solutions for the workers’ [...]
Mesa Labs Announces Third Quarter Results
03/02/2026
LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
03/02/2026
Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of miv-cel EMERYVILLE, [...]
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
03/02/2026
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE [...]
Ardelyx Receives New Patent for Tenapanor
03/02/2026
New patent covers IBSRELA® and XPHOZAH® and expires in 2042 WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]
SRx Health Solutions Significantly Reduces Short Position of Cryptocurrency Portfolio Amidst Current Market Volatility
03/02/2026
NORTH PALM BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced it has significantly reduced its short position across its cryptocurrency [...]
Vivos Inc Updates Human Therapy Progress in India
03/02/2026
Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive update on the ongoing human therapy demonstrations in India using RadioGel ® Precision [...]
Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
03/02/2026
This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US The newly cleared capability provides radiologists with a 2D image generated directly from the tomosynthesis [...]
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
03/02/2026
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year than stroke, Alzheimer’s [...]
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
03/02/2026
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold ® (migalastat) in Fabry disease and [...]
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
03/02/2026
Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a [...]
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
03/02/2026
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41 st Asia-Pacific Academy of Ophthalmology (APAO [...]
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
03/02/2026
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today [...]
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
03/02/2026
Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 [...]
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
03/02/2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today [...]
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
03/02/2026
Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced [...]
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
03/02/2026
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE [...]

Pages